drugset / Trial / NCT05684965
XTX301 in Patients With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.
Timeline
- Start
- 2023-05-11
- Primary completion
- 2028-09
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XTX301 | Protein / enzyme biologic | — | — |